Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.

Ther Adv Med Oncol · 2020 · PMC7222249 · PMID 32426048

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

A notable trend of overall survival (OS) between the atezolizumab plus nab-paclitaxel and nab-paclitaxel arms was observed in the PD-L1-positive subgroup (median OS time: 25.0 months versus 15.5 months; HR for death, 0.62; 95% CI, 0.45–0.86).

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.